期刊文献+

HCMV UL97 mRNA序列特异性M1GS的构建及其体外切割活性研究(英文) 被引量:1

Construction of An Effective M1GS Ribozyme TargetingHCMV UL97 mRNA Segment in Vitro
下载PDF
导出
摘要 HCMVUL97基因编码一种蛋白激酶,该酶参与调控病毒DNA的复制和衣壳的形成,且序列异常保守,可作为抗HCMV治疗的重要靶位。基于HCMVUL97mRNAT3位点附近的序列,设计一段与该位点互补的引导序列(GuideSequence,GS),并将其与大肠杆菌核酶P催化亚基(M1RNA)的3′末端共价连接,构建了一种序列特异性的M1GS(M1-T3)。体外实验证实,所构建的M1-T3可与UL97mRNA的T3位点特异性结合并产生有效的切割作用。进一步研究M1-T3的结构与其对底物片段靶向切割活性的关系,结果发现在M1RNA与GS之间增加一段88核苷酸桥连序列的M1-T3(即M1-T3*),其靶向切割活性大大增强。此外,去除M1-T33′末端的CCA序列,其靶向切割活性将基本丧失。上述结果表明,这段桥连序列和3′末端的CCA序列是M1-T3重要的结构元件。这不仅有助于阐明M1GS与其底物的相互作用机制,同时也为进一步评价M1-T3在体内对UL97基因表达及病毒复制的抑制活性奠定了基础。 A sequence-specific M1GS ribozyme (M1-T3) was constructed by covalently linking an oligonucleotide (guide sequence,GS) to the 3' terminus of M1 RNA ,the catalytic subunit of RNase P from Escherichia coll. The engineered ribozyme is targeted to the mRNA sequence encoding a protein kinase (UL97)of HCMV and could effectively cleave the mRNA segment in vitro. Further studies about the significance of some structural elements in the M1GS (e. g. the 3' CCA tail sequence and a bridge sequence between the 3' terminus of M1 RNA and the 5' terminus of the GS) were carried out. The results showed that the bridge sequence of 88 nucleotides in a mutated M1GS ( i. e. M1-T3* ) dramatically increased the cleavage activity to the substrate in vitro. Moreover,the 3'CCA tail sequence was confirmed to be a necessary element for the cleavage activity of M1GS ribozyme. These data we got in the study will help in understanding the interaction between the M1GS RNA and its substrate,and will markedly facilitate the research of a general gene targeting agent for anti-HCMV applications.
出处 《Acta Genetica Sinica》 SCIE CAS CSCD 北大核心 2005年第11期1205-1212,共8页
基金 国家自然科学基金(编号:30370776) 广东省自然科学基金(编号:36703,021162和000718)~~
关键词 核酶P(RNase P) M1GS 人巨细胞病毒 UL97 Ribonuclease P (RNase P) M1GS HCMV UL97
  • 相关文献

参考文献27

  • 1Numazaki K,Asanuma H,Chiba S. Latent infection and reactivation of human cytomegalovirus. Human Immunology Volume,2004,5:403 - 408.
  • 2Revello, Maria G, Gerna G. Pathogenesis and prenatal diagnosis of human cytomegalovirus infection. Journal of Clinical Virology, 2004,29 ( 2 ):71 - 83.
  • 3Palella F J,Delaney K M,Moorman A C,Loveless M O,Fuhrer J ,Satten G A. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. New Engl J Med,1998,338:853-860.
  • 4Fowler K B,Stagno S,Pass R F,Britt W J,Boll T J,Alford C A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. New Engl J Med,1992,326:663 - 667.
  • 5Jacobson M A,Drew W L,Feinberg J,O'Donnell J J,Whitmore P V,Miner R D,Parenti D.Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis,1991, 163:1348 - 1351.
  • 6Azad R F, Brown-Driver V, Buckheit R W,Anderson K P.Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antivir Res,1995,28:101-111.
  • 7Baldanti F, Underwood M R, Stanat S C, Biron K K, Chou S,Sarasini A. Single amino acid changes in the DNA polymerase confer foscarnet resistance and stow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three doubleresistant human cytomegalovirus strains recovered from pa-tients with AIDS. J Virol, 1996,70 : 1390 - 1395.
  • 8Hampel A. The hairpin ribozyme :discovery, two-dimensional model,and development for gene therapy. Prog Nucleic Acid Res Mol Biol, 1998,58 : 1 - 39.
  • 9Sawer N,Cantin E M,Chang P S,Zaia J A, Ladne P A,Stephens D A, Rossi J J. Ribozymes as potential anti-HIV-1 therapeutic agents. Science, 1990,247 :1222 - 1225.
  • 10Gervaix A,Li X, Kraus G F. Wong-Staal,Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J Virol,1997,71:3048 -3053.

二级参考文献16

  • 1赵西林,陈雄伟,陈雅文,刘戈,孙宝勇,陈德风.核酶设计、合成与克隆的一种新方法[J].生物化学与生物物理进展,1993,20(5):376-380. 被引量:7
  • 2Trang P, Lee M, Nepomuceno E, Kim J, Zhu H, Liu F. Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli[J]. Proc Natl Acad Sci U S A, 2000 May,
  • 3Markus Wagner, Detlef Michel, Peter Schaarschmidt, et al. Comperison between Human Cytomegalovirus pUL97 and Murine Cytomegalovirus (MCMV) pM97 Expressed by MCMV and Vaccinia Virus: pM97 Does Not Confer Ganciclovir Sensitivity[J]. Jof Virology, November 2
  • 4Yow MD, White NH, Taber LH, et al. Acquisition of cytomegalovirus infection from birth to 10 years: a longitudinal serologic study[J]. J Pediatr, 1987, 110:37 - 42.
  • 5Joanna Kufel. Different cleavage sites are aligned differently in the active site of M1 RNA, the catalytic subunit of Escherichia coli RNase P[J]. Proc. Natl. Acad. Sci. USA, June 1996, (93) :6085- 6090.
  • 6Stinki MF, Malone CL, Hermiston TW, Liu B. Regulation of human Cytomegalovirus transplation[ M]. Boca Raton: CRC Press, 1991,245 - 260.
  • 7Fenyong Liu, RNase P- mediated inhibition of cytomegalovirus protease expression and viral DNA encapsidation by oligonucleotide external guide sequences [ J ]. PNAS, December 18, 2001, 98 (26):14831 - 14836.
  • 8Yan Yuan. Targeted cleavage of mRNA by human RNase P[J],Proc. Natl. Acad. Sci. USA, September 1992, (89) :8006 - 8010.
  • 9N. Kyle Tanner, Ribozymes: the characteristics and properties of catalytic RNAs[J]. FEMS Microbiology Reviews, 1999, (23) :257- 275.
  • 10Diane Kawa and Fenyong LIU, Inhibition of viral gene expression by human ribonuclease P[J]. RNA, 1998, (4): 1397- 1406.

共引文献2

同被引文献7

  • 1郑永霞,李弘剑,李月琴,陈浩军,唐冬生,张欣,周天鸿.桥序列在构建人工核酶M1GS中的作用[J].暨南大学学报(自然科学与医学版),2005,26(2):151-155. 被引量:4
  • 2PHONG T, JARONE L, AHMED FK, et al. Effective inhibition of HSV-1 gene expression and growth by engineered RNase P ribozyme[ J]. Nucleic Acids Research,2001, 29(24) :5 071.
  • 3PHONG T, AHMED K, JARONE L, et al. RNase P ribozymes for the studies and treatment of human cytomegalovirus infections [ J ]. Journal of Clinical Virology, 2002, 25 :S63.
  • 4PHONG T, KIM K, LIU F. Developing RNase P ribozymes for gene-targeting and antiviral therapy[ J ]. Cell Microbiol, 2004,6(6) :499.
  • 5ZOU H, CHAN K, TRANG P,et al. General design and construction of RNase P ribozymes for gene-targeting applications[ J]. Methods Mol Biol, 2004,252:385.
  • 6ANNIKA H,THOMAS P,TILMAN Z, et al. Exploring the minimal substrate requirements for trans- cleavage by RNase P holoenzymes from escherichia coli and bacillus subtilis [ J]. Molecular Microbiology,2001,41 ( 1 ) : 131.[7]ANNIKA H,THOMAS P,TILMAN Z, et al. Exploring the minimal substrate requirements for trans- cleavage by RNase P holoenzymes from escherichia coli and bacillus subtilis [ J]. Molecular Microbiology,2001,41 ( 1 ) : 131.
  • 7ASTRID S. Ribonuclease P: the diversity of a ubiquitous RNA processing enzyme [ J ]. FEMS Microbiology Reviews, 1999, 23 (3) :391.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部